Stocks · News reference
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The article covers various investment themes and sectors including robotics and AI adoption, pharmaceuticals driven by aging populations, airline industry opportunities, and oil/natural gas earnings growth. It also discusses employment data showing Leisure & Hospitality leading job growth, and provides analysis of major tech companies like Amazon, AbbVie, and Alibaba facing different growth drivers and challenges.
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
The article covers various market developments including August employment data expectations (55,000 new jobs, 4.2% unemployment rate), sector performance with Leisure & Hospitality leading job growth, and analysis of multiple stock sectors including biotech, gold stocks, airlines, and pharmaceuticals. It also discusses Space ETFs and various investment opportunities across different market segments.
The article covers various market developments including August employment data expectations (55,000 new jobs, 4.2% unemployment rate), sector performance with Leisure & Hospitality leading job growth, and analysis of multiple stock sectors including biotech, gold stocks, airlines, and pharmaceuticals. It also discusses Space ETFs and various investment opportunities across different market segments.
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $400 to $435.
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.